Cytogenetically normal acute myeloid leukemia (CN-AML) accounts for 40%-50% of all AML cases. Despite advances in understanding the molecular pathophysiology of CN-AML, its clinical outcome remains unsatisfactory and unpredictable. To investigate its clinical implication in CN-AML, we measured the expression of prohibitin 2 (PHB2) using immunohistochemical staining (IHCS) of paraffin-embedded bone marrow sections from 134 CN-AML patients. IHCS results were semi-quantitatively scored. Clinical outcome was analyzed in comparison with other prognostic markers, including NPM1 polymorphism and FLT3 internal tandem duplication, and WT1 and BAALC mRNA expression. Except for BAALC mRNA expression, the known molecular markers showed no prognostic effect in the CN-AML patients. PHB2 protein overexpression was significantly associated with adverse prognosis in CN-AML patients. The PHB2 protein expression status may serve as an independent prognostic indicator in CN-AML.

中文翻译：

---

Prohibitin 2 蛋白的过表达与细胞遗传学正常急性髓细胞白血病的不良预后相关。

细胞遗传学正常的急性髓性白血病 (CN-AML) 占所有 AML 病例的 40%-50%。尽管在理解 CN-AML 的分子病理生理学方面取得了进展，但其临床结果仍然不令人满意且不可预测。为了研究其在 CN-AML 中的临床意义，我们使用来自 134 名 CN-AML 患者的石蜡包埋骨髓切片的免疫组织化学染色 (IHCS) 测量了抑制素 2 (PHB2) 的表达。对 IHCS 结果进行半定量评分。将临床结果与其他预后标志物进行比较，包括NPM1多态性和FLT3内部串联重复，以及WT1和BAALC mRNA 表达。除了BAALCmRNA表达，已知的分子标志物对CN-AML患者没有预后作用。PHB2蛋白过表达与CN-AML患者的不良预后显着相关。PHB2 蛋白表达状态可作为 CN-AML 的独立预后指标。